Skip to content
About Us
Company Profile
Management
Investors
Contact
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Sepsis & Septic Shock
Adrenomedullin
News & Events
Press releases
Media coverage
Events
Career
Menu
About Us
Company Profile
Management
Investors
Contact
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Sepsis & Septic Shock
Adrenomedullin
News & Events
Press releases
Media coverage
Events
Career
Article in BioCentury: Adrecizumab shows apparent mortality benefit in septic shock trial
29. April 2021
April 2021,
by Stephen Hansen
Download